Prelude Therapeutics (PRLD) Other Non-Current Assets (2020 - 2026)

Prelude Therapeutics has reported Other Non-Current Assets for 7 years, with the latest figure at $3.2 million in Q1 2026.

• Quarterly Other Non-Current Assets fell 20.0% year-over-year to $3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (down 20.0% YoY) and the FY2025 annual result came in at $110000.0, changed 0.0% from the prior year.
• Other Non-Current Assets climbed to $3.2 million in Q1 2026 per PRLD's latest filing, from $110000.0 in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $12.5 million in Q3 2023 and troughed at $110000.0 in Q4 2024.
• A 5-year average of $3.0 million and a median of $3.2 million in 2025 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets jumped 1674.26% in 2022, then sank 96.75% in 2024.
• Over 5 years, Other Non-Current Assets stood at $5.4 million in 2022, then slumped by 94.51% to $295000.0 in 2023, then tumbled by 62.71% to $110000.0 in 2024, then changed by 0.0% to $110000.0 in 2025, then soared by 2840.91% to $3.2 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $3.2 million, $110000.0, and $3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.